GRCL · Gracell Biotechnologies
Acquired Company
AstraZeneca completed the acquisition of Gracell Biotechnologies on February 22, 2024.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for cancer treatment in the People's Republic of China. The company is headquartered in Suzhou, China.
Market Cap
989.9M
52 Wk Range
$0.00 - $0.00
Previous Close
$10.25
Open
$10.25
Volume
N/A
Day Range
$10.25 - $10.25
Enterprise Value
N/A
Cash
1.677B
Avg Qtr Burn
N/A
Insider Ownership
16.39%
Institutional Own.
63.11%
Qtr Updated
Sep 30th 2023